Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
NCT05977673Phase 2Recruiting
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2024
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by Fondazione Italiana Linfomi. Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT05977673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977673.